Tesamorelin (Egrifta) is a synthetic GHRH analogue FDA-approved for visceral fat reduction in HIV-associated lipodystrophy. Phase III trials showed 15u201317% VAT reduction by CT scan at 6 months. Effects reverse within 6 months of stopping u2014 it treats, not cures.
Overview
Reconstitution Table (2 mL mL BAC water u2192 2 mg)
| Dose | Draw (U-100) | Timing |
| 2 mg daily | 4 Units (2 mg/mL) | Morning, SC abdomen |
Reconstitute with 2 mL sterile water for injection (not BAC water u2014 per prescribing guidelines). 2 mg = 4 Units on U-100. Rotate injection sites within the abdomen.
FDA-approved (Egrifta SV) for HIV-associated lipodystrophy. Off-label use for general body composition is not approved. Research use only outside approved indication.
Potential Benefits & Side Effects
Potential Benefits
- Selective visceral fat reduction (15u201317%)
- FDA-approved safety profile
- No significant effect on peripheral fat
- Preserves pituitary axis
Possible Side Effects
- Injection-site reactions (erythema, pruritus)
- Oedema
- Arthralgia
- Glucose elevation (monitor HbA1c)
Storage Instructions
Lyophilized Powder
- Short-term (<3 months): Refrigerate at 2u00b0Cu20138u00b0C
- Long-term: Freeze at u221220u00b0C or lower
- Protect from light and moisture
- Allow vial to reach room temperature before opening
Reconstituted Solution
Reconstituted Tesamorelin should be used immediately or stored at 2u20138u00b0C for up to 24 hours. Do not freeze reconstituted solution.
References
Important Note
This protocol guide is for educational and research purposes only. It is not medical advice. Always consult a qualified healthcare professional before using any peptide compound.